West Pharmaceutical Services (WST) return on equity (ROE)
West Pharmaceutical Services (WST) earned a return on equity of 15.5% in fiscal 2025 (the year ended December 31, 2025). That is 2.8 percentage points lower than the 18.4% of fiscal 2024. Figures as of 17 Nov 2026, 20:29 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Return on equity, fiscal 2025
- 15.5%
- Change on fiscal 2024
- −2.8 pts
- Highest on record
- 28.3%fiscal 2021
- Lowest on record
- 9.3%fiscal 2015
- Fiscal years on record
- 182008–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
West Pharmaceutical Services return on equity (ROE), in more detail
Across the 18 fiscal years on record (2008–2025), the highest was 28.3% in fiscal 2021 and the lowest 9.3% in fiscal 2015. The fiscal 2025 figure is higher than in 65% of the 17 earlier fiscal years on record, whose median is 13.3%.
Return on equity by fiscal year
West Pharmaceutical Services return on equity (ROE), year by year
| Fiscal year | Return on equity | Change | Year ended |
|---|---|---|---|
| 2025 | 15.5% | 2.8 pts down | |
| 2024 | 18.4% | 2.2 pts down | |
| 2023 | 20.6% | 1.2 pts down | |
| 2022 | 21.8% | 6.5 pts down | |
| 2021 | 28.3% | 9.7 pts up | |
| 2020 | 18.7% | 3.3 pts up | |
| 2019 | 15.4% | 0.5 pts up | |
| 2018 | 14.8% | 3.0 pts up | |
| 2017 | 11.8% | 1.1 pts down | |
| 2016 | 12.9% | 3.5 pts up | |
| 2015 | 9.3% | 3.9 pts down | |
| 2014 | 13.3% | 0.9 pts up | |
| 2013 | 12.4% | 1.3 pts up | |
| 2012 | 11.1% | 0.5 pts down | |
| 2011 | 11.5% | 1.1 pts up | |
| 2010 | 10.4% | 2.1 pts down | |
| 2009 | 12.5% | 5.1 pts down | |
| 2008 | 17.7% | — |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
How to read it
It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.
Return on equity at health care companies of similar size
| Company | Return on equity | Fiscal year |
|---|---|---|
| Labcorp Holdings LH | 10.2% | 2025 |
| DexCom DXCM | 30.5% | 2025 |
| Koninklijke Philips PHG | 8.2% | 2025 |
| Roivant Sciences ROIV | -6.6% | 2026 |
| West Pharmaceutical Services WST | 15.5% | 2025 |
| Quest Diagnostics DGX | 13.8% | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
West Pharmaceutical Services, figure by figure
- West Pharmaceutical Services market cap
- West Pharmaceutical Services revenue
- West Pharmaceutical Services earnings
- West Pharmaceutical Services earnings per share (EPS)
- West Pharmaceutical Services P/E ratio
- West Pharmaceutical Services P/S ratio
- West Pharmaceutical Services P/B ratio
- West Pharmaceutical Services free cash flow
- West Pharmaceutical Services operating margin
- West Pharmaceutical Services dividend
- West Pharmaceutical Services shares outstanding
- West Pharmaceutical Services total debt
- West Pharmaceutical Services cash on hand
- West Pharmaceutical Services total assets
- West Pharmaceutical Services return on invested capital (ROIC)
West Pharmaceutical Services (WST) overview: price, valuation and scorecardAll health care companies by market value
West Pharmaceutical Services return on equity (ROE): questions and answers
What is West Pharmaceutical Services's return on equity?
West Pharmaceutical Services (WST) earned a return on equity of 15.5% in fiscal 2025 (the year ended December 31, 2025). That is 2.8 percentage points lower than the 18.4% of fiscal 2024.
Is West Pharmaceutical Services's return on equity high or low compared with its own history?
The fiscal 2025 figure is higher than in 65% of the 17 earlier fiscal years on record, whose median is 13.3%.
What are the highest and lowest return on equity figures on record for West Pharmaceutical Services?
Across the 18 fiscal years on record (2008–2025), the highest was 28.3% in fiscal 2021 and the lowest 9.3% in fiscal 2015.
How is West Pharmaceutical Services's return on equity calculated?
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: return on equity (ROE)
All stocks guides →- Return on invested capital (ROIC) vs ROE and ROA
Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “West Pharmaceutical Services (WST) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/WST/roe
Underlying data: the company's filings with the SEC and Yahoo Finance.